Caliway Biopharmaceuticals
$0
0
+$0+0% Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MayExpected
Expected EPS
-0.00532457
Actual EPS
N/A
Financials
-1,323.54%Profit Margin
Unprofitable2.75MRevenue
-36.34MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CLBPF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
Show more...
CEO
ISIN
TW0006919004
Listings
0 Comments
Share your thoughts
FAQ
What is Caliway Biopharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Caliway Biopharmaceuticals stocks are traded under the ticker CLBPF.
When is the next Caliway Biopharmaceuticals earnings date?▼
Caliway Biopharmaceuticals is going to release the next earnings report on May 18, 2026.
What is Caliway Biopharmaceuticals revenue for the last year?▼
Caliway Biopharmaceuticals revenue for the last year amounts to 2.75M USD.
What is Caliway Biopharmaceuticals net income for the last year?▼
CLBPF net income for the last year is -36.34M USD.
When did Caliway Biopharmaceuticals complete a stock split?▼
Caliway Biopharmaceuticals has not had any recent stock splits.